Stonepine Capital Management LLC Makes New $539.04 Million Investment in ImageneBio, Inc. $IMA

Stonepine Capital Management LLC bought a new stake in ImageneBio, Inc. (NASDAQ:IMA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 96,172 shares of the company’s stock, valued at approximately $539,044,000. Stonepine Capital Management LLC owned about 0.85% of ImageneBio at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Blue Owl Capital Holdings LP acquired a new stake in ImageneBio during the 2nd quarter worth approximately $5,414,000. Monashee Investment Management LLC acquired a new position in ImageneBio in the 4th quarter valued at approximately $632,000. Cable Car Capital LP acquired a new position in ImageneBio in the 2nd quarter valued at approximately $4,611,000. Trails Edge Capital Partners LP acquired a new position in ImageneBio in the 2nd quarter valued at approximately $1,663,824,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of ImageneBio during the fourth quarter valued at $183,000. 75.00% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on IMA shares. Wall Street Zen lowered shares of ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. Wedbush restated an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. Finally, HC Wainwright assumed coverage on ImageneBio in a research report on Friday, August 21st. They issued a “buy” rating and a $28.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, ImageneBio has a consensus rating of “Hold” and a consensus target price of $29.00.

ImageneBio Stock Performance

NASDAQ:IMA opened at $5.33 on Friday. ImageneBio, Inc. has a 52 week low of $3.94 and a 52 week high of $13.98. The firm’s fifty day moving average is $5.77 and its 200-day moving average is $5.81. The firm has a market cap of $60.50 million, a P/E ratio of -1.16 and a beta of 0.76.

ImageneBio (NASDAQ:IMA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.27. As a group, sell-side analysts anticipate that ImageneBio, Inc. will post -3.23 earnings per share for the current year.

ImageneBio Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.